ANITA AGARWAL, USA
Anita Agarwal, M.D., is a Vitreoretinal consultant at West Coast Retina and Adjoint Professor of Ophthalmology at the Vanderbilt Eye Institute. Dr. Agarwal specializes in medical and surgical diseases of the retina and uvea and has a special interest in uncommon and inherited retinal diseases. She received her medical degree from Kasturba Medical College, Mangalore, India, and ophthalmology residency and fellowship training at the Post Graduate Institute of Medical Education & Research (Amod Gupta), Chandigarh, India and the Universities of Florida, Vanderbilt (Gass) and West Virginia (Lionel Chisholm), USA.
Her clinical interests include a variety of infectious, inflammatory, degenerative, and dystrophic medical retinal disorders and surgical vitreoretinal diseases. She is a member of the Macula Society and the Retina Society and has been recognized as one of America's Best doctors, Castle Connoly's top doctors, and top ophthalmologists. She is the recipient of the 2014 J. Donald Gass Medal for outstanding contributions in the study of Macular Diseases awarded by the Macula Society and the 2015 Optic UK Lecture Medal awarded by the Royal College of Ophthalmologists, UK. She has delivered many named lectures, been an invited speaker world wide, and has also received honor awards from the American Academy of Ophthalmology and the American Society of Retina Specialists.
She is the author of the Fifth Edition of the Gass' Atlas of Macular Disease, and she has coauthored landmark research papers on the genetics of macular degeneration. She serves on the editorial boards of journals: Ophthalmology, Ophthalmology – Retina, Retina Cases and Brief Reports, and American Journal of Ophthalmology Case Reports.
JENNIFER ARNOLD, AUSTRALIA
Jennifer Arnold is a Sydney based medical retinal specialist and researcher.
Trained at Sydney Eye Hospital followed by a medical retinal fellowship with Professors Gabriel Coscas and Gisele Soubrane in Paris, she worked as a consultant in Aberdeen Scotland before returning to Sydney where she is currently a partner at Marsden Eye Specialists. Working many years with John and Shirley Sarks set the foundation for an ongoing focus in age-related macular degeneration which remains one of her main interests as well as retino-vascular disease.
Jennifer maintains a strong involvement in clinical research: she has been involved as principal investigator in over 50 international clinical trials of new treatments for a range of retinal conditions and in the analysis of real world outcomes of the management of retinal diseases.
FRANCESCO BANDELLO, ITALY
Francesco Bandello is Professor and Chairman at the Department of Ophthalmology at University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy. He is Academic Dean of "Corso di Laurea Specialistica/Magistrale in Medicina e Chirurgia" at the same University. Professor Bandello is Past-President of EURETINA, President of Academia Ophthalmologica Europea and Vice-President of EuroLam. He is Co-Editor of the European Journal of Ophthalmology and former board member of the Club Jules Gonin and Macula Society.
He is member of Executive Board of ESASO (European School for Advanced Studies in Ophthalmology) Foundation, member of the Academia Ophthalmologica Internationalis and the Accademia Nazionale di Medicina. Prof. Bandello is co-author of 9 books and he serves as a peer reviewer for grant applications for the NEI. He has authored or co-authored 367 Pub-Med articles and he served as trained Principal Investigator in several clinical trials performed following ICH/GCP and mainly concerning retinal diseases.
CAROLINE BAUMAL, USA
Caroline R. Baumal, MD is an Associate Professor of Ophthalmology and Director of Retinopathy of Prematurity Service at New England Eye Center, Tufts Medical Center in Boston, MA. She specializes in diseases and surgery of the retina and vitreous. Her research interests include novel retinal imaging and diagnostics, drug development and delivery to the posterior segment. These developed during her first retina fellowship at New England Eye Center in 1995 with Carmen Puliafito where the first prototype OCT device was being developed for clinical use and emerging therapies such as the ganciclovir implant and photodynamic therapy were being investigated. Her clinical interests include age-related macular degeneration, diabetic retinopathy, complex vitreoretinal surgery and retinopathy of prematurity.
Dr. Baumal completed Medical School and Ophthalmology Residency at the University of Toronto after undergraduate studies at McGill University. She completed two fellowships: one at New England Eye Center in Boston for Medical Retina and Lasers and the other in Vitreoretinal Diseases and Surgery at Wills Eye Hospital in Philadelphia. Dr. Baumal is Board Certified by the American Board of Ophthalmology and has received the Senior Achievement Award from the American Academy of Ophthalmology. Dr. Baumal has authored over 100 peer-reviewed papers and 25 book chapters on retinal diseases. She is actively involved in teaching vitreoretinal fellows and residents and was previously Director of the residency program. She lives in Boston with her family of 3 young boys who consistently improve her stamina and patience!
DAVID STUART BOYER, USA
David S. Boyer, M.D. is a Board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous. Dr. Boyer is Senior Partner at Retina-Vitreous Associates Medical Group with offices in Los Angeles, Beverly Hills, North Hollywood, Torrance, Pasadena and Tarzana, California.
Dr. Boyer is a Clinical Professor of Ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA.
He has an extensive research background and is currently an investigator for various clinical trials. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema.
A widely-published author and avid lecturer, Dr. Boyer lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases.
NEIL MICHAEL BRESSLER, USA
Neil M. Bressler, M.D., graduated from the Johns Hopkins University School of Medicine in 1982 and completed an ophthalmology residency at Harvard Medical School's Massachusetts Eye and Ear Infirmary in 1986. He joined the Wilmer Eye Institute (Department of Ophthalmology) faculty at Johns Hopkins in 1988 and currently is Chief of the Retina Division with 19 full-time clinical faculty in retina. He has an endowed chair as the inaugural James P. Gills Professor of Ophthalmology and has authored over 375 peer-reviewed publications. Dr. Bressler continues to work on the NIH-sponsored Diabetic Retinopathy Clinical Research Network that he chaired for 7 years, and currently chairs the National Eye Institute's Data and Safety Monitoring Committee for intramural clinical trials. He also has been Chair of the FDA Ophthalmic Devices Panel, and President of the Macula Society. He currently serves as Editor-in-Chief of JAMA Ophthalmology and has been on The JAMA Network Editorial Board of JAMA since 2013. Apart from medicine, he served as Vice Chair of the Board of Trustees for the Interlochen Center for the Arts in Michigan, where he shared responsibility for engaging and inspiring people through excellence in educational, artistic and cultural programs in the arts, recently becoming only the 12th Life Trustee for the Interlochen Center for the Arts in 90 years.
SUSAN B. BRESSLER, USA
Dr. Susan Bressler graduated summa cum laude from Smith College, Northampton, MA, USA in 1978. She attended The Johns Hopkins University School of Medicine where she was elected to Alpha Omega Alpha and received the Paul Ehrlich Award for Clinical Investigation at Hopkins' Young Investigators' Day in 1982 for her first project in ophthalmology on age-related macular degeneration. After completing an internship in internal medicine at Johns Hopkins Hospital in 1983, Dr. Bressler pursued an ophthalmology residency at Harvard Medical School's Massachusetts Eye & Ear Infirmary. After a fellowship in medical retina at Wilmer and additional retinal surgery training at Massachusetts Eye & Ear Infirmary (each supported by a Heed and Heed/Knapp fellowship), she returned to Baltimore in 1988 to join the faculty at The Wilmer Eye Institute at Johns Hopkins. In 2000, she became only the second woman physician promoted to Professor of Ophthalmology at The Wilmer Eye Institute. In May 2004 she was inducted as the inaugural recipient of the Julia G. Levy, PhD Professor of Ophthalmology.
Dr. Bressler has a large national and international referral practice at The Wilmer Eye Institute. In addition, she has published 231 peer reviewed articles and 58 book chapters. Editorial Board positions have included American Journal of Ophthalmology, Survey of Ophthalmology, Retina, EyeNet Magazine, the Health After 50: The Johns Hopkins Medical Letter, and the Wilmer Retina Update.
Her main research interest has been collaborative efforts in clinical trials —serving as principal investigator of an image reading center that has served as a central unit for many clinical trials and epidemiologic investigations, as Vice Chair of the Diabetic Retinopathy Clinical Research Network (DRCR.net), and as principal investigator of a participating clinical center in several major clinical trials. Most studies have specific emphasis on the treatment of both non-neovascular and neovascular age-related macular degeneration and all aspects of diabetic retinopathy. She has received the Rosenthal Award from the Macula Society, the Olga Keith Weiss Scholar Award from Research to Prevent Blindness (RPB), an RPB Physician-Scientist Award, a Senior Achievement Award and a Lifetime Achievement Award from the American Academy of Ophthalmology, a Senior Honor Award from The American Society of Retina Specialists, the Gertrude Pyron Award for Lifetime Achievement of Outstanding Research, and was the Inaugural recipient of the Neil Miller Medical Student Teaching Award at The Johns Hopkins University School of Medicine. She has given several named lectures throughout the US, and has been invited to speak at numerous national and international meetings.
USHA CHAKRAVARTHY, UK
Usha Chakravarthy is Professor of Ophthalmology and Vision Sciences in the Queen's University of Belfast. She has a varied portfolio of research interests and she has worked on the cell and molecular biology of vasoactive retinal peptides and profiled the alterations in gene expression in the retina under conditions of simulated hyperglycemia in experimental in vitro and vivo studies. Her current research involves studies on understanding of retinal and choroidal vascular diseases as well as degenerative aging changes contributing to sight loss in older adults. She is recognised internationally for her work on age-related macular degeneration and diabetic retinopathy. Her interests lie in the pathogenesis and key risk factors including gene and environment interactions and clinical management of these disorders. She has in excess of 300 publications and many book chapters. She was chairperson of the ophthalmology specialty group for UKCRN and is a member of the Royal College of Ophthalmologists Academic Group. On an international level she is on the advisory panel for the AMD
ITAY CHOWERS, ISRAEL
Itay Chowers is a Professor of Ophthalmology at the Hadassah - Hebrew University Medical Center. Dr. Chowers has completed medical school at the Hebrew University and an Ophthalmology residency at Hadassah. He then performed vitreoratinal and research fellowships at the Wilmer Eye Institute of the Johns Hopkins University School of Medicine (2000-2003). Prof. Chowers is a past chairman of the Israeli retina specialists association (2013-2016), and was the head of ophthalmology education at the Hebrew University School of Medicine (2011-2014). He is serving as faculty member in the retina service at Hadassah and is involved in multiple clinical trials focused on retinal diseases in general and Age Related Macular Degeneration (AMD) in particular. Dr. Chowers is also a PI of a research group which focuses on the study of the genetics and pathogenesis of AMD. His research was summarized in 94 manuscripts that were published in peer-reviewed literature.
SALOMON YVES COHEN, FRANCE
Salomon Y. Cohen received his MD from Paris University in 1990. He performed most of his ophthalmology residency in departments specialized in retina, and his fellowship at the Creteil University Eye Clinic, chaired by Professor Gabriel Coscas. He completed a master in biology and a PhD in Neurosciences. He is currently practicing as Retina specialist in private practice and in the department of ophthalmology of Creteil (Professor Souied). He authored 8 books devoted to fluorescein angiography, indocyanine green angiography, ageing eye, age-related macular degeneration, low vision rehabilitation, and an 8 volumes' book named RETINE. He authored more than 140 papers, most of them in peer-reviewed international journals. He is associate Professor in the University of Creteil, recipient of the American Academy of Ophthalmology Achievement Award, and member of the Editorial Board of the journal RETINA.
GABRIEL COSCAS, FRANCE
Gabriel COSCAS was trained at University of Paris. He established Department of Ophthalmology in 1970 in Créteil (University Paris XII) and served as Professor of Ophthalmology and Chairman until 1999. President of French Retina Society He devoted most of his activity on macular diseases.
He organized the first randomised clinical trial on macular photocoagulation for AMD in France. 1977-1982. Author and co-author of over 450 peer review papers. Author and co-author of over 450 peer review papers and many books, including "Atlas of ICG angiography", 2004, Elsevier. "OCT and AMD", 2009, Springer Publ. and a book on "Macular oedema", Karger Edit 2010. Dr Coscas has been Guest of Honor of the American Academy of Ophthalmology (1985). Dr Coscas has been elected member of the ACADEMIA OPHTHALMOLOGICA INTERNATIONALIS, in 1988 and served as General Secretary since 1994 and as first Vice President since 2002. Dr Coscas was a founding Member of ACADEMIA EUROPEA OPHTHALMOLOGICA and serve as First Vice President from 2005. Founding member of Global Alliance against Trachoma at WHO
He received many awards and lectures , including the Oxford Lecture and Award, 1990; the Jules Stein Lecture and Award, 1992; the Michaelson Lecture and Award, 1995; Lecturer Nara, Japan, 1995; the Award of Merit of the Retina Research Foundation, at the Jules Gonin Club meeting, in Bern in 1996;the JDM. Gass Medal at the Macula Society (1996); the Tunisian Ophthalmological Society Gold Medal (1995); the Mediterranean Ophthalmological Society Gold Medal and Award 1998; the Jules François Lecture in Paris 2001; the Gold Medal of the Algerian Society of Ophthalmology (2005 the Academia Ophthalmologica Internationalis Lecture, Jerusalem; the Gold Medal of the Algerian Society of Ophthalmology (2005); the EURETINA Lecture in Barcelona, in 2007.
He was elected Honor Member of Club Jules Gonin, (1998) and Honor Member of La Société Française d'Ophtalmologie (1998); and Honor Member of Instituto Barraquer in Barcelona, 2002. He was honored as first recipient of the "Gabriel COSCAS Lecture" 2001, founded in Rome and of the "Gabriel Coscas Lecture" and Award, founded in Paris - Macula Meeting 2002. A "Gabriel Coscas Price" for excellence in research in retina has been established in 2008.
Gabriel Coscas was elevated to the dignity of "Commandeur de la Légion d'honneur » in Avril 2007 by the Président de la République Française.
CATHERINE CREUZOT GARCHET, FRANCE
Catherine is Professor of Ophthalmology and Chair at the University Hospital of Dijon, Burgundy, France. She is the head of Research Pole in the University Hospital of Dijon. She is past President of the French Society of Ophthalmology, past President of the French Board Professors of Ophthalmology, past president of the European Board of Ophthalmology and she is currently Secretary General of EVER (European Vision and Eye Research). She is member of the national university council.
She is also the co-director of the Eye and Nutrition Laboratory at the INRA (National Institute for Research in Agronomy).
Her main field of interest is medical and surgical retina.
KARL CSAKY, USA
Dr. Csaky is the T. Boone Pickens Director of the Clinical Center of Innovation for Age-Related Macular Degeneration, Managing Director and Chief Medical Officer of the Retina Foundation of the Southwest and a partner at the Texas Retina Associates. His main area of interest is studying both clinical and drug delivery research as it pertains to age-related macular degeneration (AMD). In particular Dr. Csaky is involved in various clinical trials on dry AMD, is studying vision function assessments of patients with various stage of AMD and developing drug delivery approaches for the treatment of AMD. Dr. Csaky is a member of the Macula Society, Retina Society, and American Academy of Ophthalmology, ARVO and the American Society of Retinal Specialists.
EMMETT T. CUNNINGHAM JR., USA
Dr. Emmett T. Cunningham Jr. is currently Director of the Uveitis Service at California Pacific Medical Center, Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine, Research Associate, The Francis I. Proctor Foundation, UCSF School of Medicine, Partner at West Coast Retina Medical Group, and Partner at Clarus Ventures, LLC.
Dr. Cunningham is an internationally recognized authority in the field of infectious and inflammatory eye disease, having written over 300 publications. Dr. Cunningham was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University, and a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute. He completed a residency in ophthalmology and fellowship training in Corneal Disease, External Disease and Uveitis at UCSF and The Francis I. Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital in London, and a fellowship in public health ophthalmology at the Wilmer Eye Institute in Baltimore, Maryland.
Dr. Cunningham founded and is the Chairman of the Ophthalmology Innovation Summit (www.ophthalmologysummit.com), a well-attended symposium held in conjunction with both the annual meetings of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgeons, and the American Society of Retinal Surgeons. The Ophthalmology Innovation Summit brings together leading companies, clinicians, academics and investors in the ophthalmology space. Dr. Cunningham is on the Board of The Alta Foundation, Restoration Robotics, Annexon Biosciences, ViewPoint Therapeutics, SFJ V, and GrayBug Vision. He served previously on the Boards of SARcode Biosciences (acquired by Shire) and Neomend (acquired by Bard). He is a Board observer for Avillion and Lumos and is on the Scientific Advisory Board of Aerie Pharmaceuticals and Achillion Pharmaceuticals.
Dr. Cunningham currently sees patients in the West Coast Retina Medical Group, 1445 Bush Street, San Francisco, California 94109; TP# 415 972 4600; FAX # 415 975 0999; he may be contacted e-mail: email@example.com . His online profiles are available at: http://www.proctor.ucsf.edu/faculty/emmett-t-cunningham-jr-md-phd-mph
DIANA DO, USA
Diana V. Do, MD, is a Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. She is an internationally renowned physician who specializes in the surgical and medical treatment of retinal disorders. Dr. Do is a board-certified ophthalmologist and is an expert in the management of age related macular degeneration, diabetic retinopathy, retinal vein occlusion, retinal detachment, macular hole, retinal infections, and epiretinal membrane. She incorporates state-of-the-art treatment options for her patients while treating each individual with compassion and dignity. Her goal is to provide the highest level of care for each patient. Dr. Do is a leading clinician-scientist who has authored over 150 publications in the medical literature and has contributed to over 25 book chapters. She has been the principal investigator and co-investigator on more than 45 clinical trials investigating novel treatments for retinal diseases and ocular inflammation. She has been an invited lecturer throughout the North and South America, Europe, and Asia. Furthermore, she has directed and participated in many continuing medical education courses for ophthalmologists and retina specialists throughout the United States. Before joining Stanford, Dr. Do was Associate Professor of Ophthalmology at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine in Baltimore, Maryland. At Hopkins, she was Head of the Retina Fellowship Training Program. After her tenure at Johns Hopkins, she was recruited to serve as Vice Chair of Education and Professor of Ophthalmology at the University of Nebraska College of Medicine. In addition, she was Program Director of the ophthalmology residency training program and Director of the Retinal Fellowship Training Program at Nebraska. Dr. Do was educated at the University of California at Berkeley where she graduated summa cum laude with a Bachelor of Arts in Molecular and Cellular Biology. She received her medical degree (Alpha Omega Alpha) and was a Regents Scholar at the University of California San Francisco School of Medicine. After completing her medicine internship at Massachusetts General Hospital / Harvard Medical School, she pursued both her ophthalmology training and retina fellowship at the Wilmer Eye Institute, the Johns Hopkins University School of Medicine. Her academic achievements have been recognized with numerous national awards including the Heed Ophthalmic Foundation Clinician-Scientist Award, the Ronald Michels Fellowship Foundation Award, the Honor Award from the American Society of Retina Specialists, and the
Achievement Award from the American Academy of Ophthalmology. Dr. Do has an active clinical and surgical practice while she continues to investigate novel treatments for retinal diseases. In addition, she teaches students, residents, and retina fellows at Stanford.
PRAVIN U. DUGEL, USA
Dr Dugel graduated Summa Cum Laude from Columbia University and attended UCLA School of Medicine. He then completed his residency in ophthalmology at the Doheny Eye Institute, USC School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the Doheny Eye Institute, where then was elected to serve on the faculty as the Resident Director.
Dr Dugel joined Retinal Consultants of Arizona in July, 1994. Dr Dugel has authored more than 200 papers, 35 book chapters and has been invited to lecture at prestigious meetings, Visiting Professorships and Universities worldwide. He is on the Editorial Board of several major journals.
Dr Dugel is internationally recognized as a major clinical researcher, having been a primary investigator in over 50 multicenter clinical trials. His research and educational contributions earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO).
MICHAEL ELMAN, USA
Michael J. Elman, M.D. has practiced ophthalmology for over 30 years, specializing in diseases of the retina and vitreous. Author of more than 200 publications on retinal diseases and surgery, Dr. Elman is an Assistant Professor of Ophthalmology at the Johns Hopkins University School of Medicine, where he completed his retinal training. In 1990, he was awarded the prestigious Young Scholar Award for the entire University of Maryland system. In 1996 he was elected to the American Ophthalmological Society. Dr. Elman served as the national Study Chairman of the Diabetic Retinopathy Clinical Research Network (DRCRnet) Protocol I, a national collaborative NIH supported clinical trial that that as we all know helped transform the treatment of diabetic macular edema. A member of the DRCRnet's Executive Committee, Dr. Elman has twice served as its chairman.
Certified by the American Board of Ophthalmology and a fellow of the American Academy of Ophthalmology, Dr. Elman is a graduate of Wayne State School of Medicine. He completed his internship in internal medicine at Sinai Hospital of Detroit and his residency in ophthalmology at the University of Illinois Eye Center in Chicago. He received fellowship training in Retinal Vascular Diseases at the Wilmer Eye Institute of the Johns Hopkins University School of Medicine and fellowship training in Diseases and Surgery of the Retina and Vitreous at Barnes Hospital/Retina Consultants, Ltd. of Washington University School of Medicine. Currently, he serves as the Director of Retinal Surgery at the Franklin Square Hospital Center. Dr. Elman is president and founder of the Elman Retina Group, an empathetic private practice devoted exclusively to the medical and surgical treatment of the retina and vitreous with three state-of-the-art offices conveniently located throughout the Baltimore metropolitan area. The Elman Retina Group integrates clinical research into its effort to provide exemplary patient care.
In addition to the American Ophthalmological Society and the American Academy of Ophthalmology, Dr. Elman is a member of the Macula Society, the Association for Research in Vision and Ophthalmology (ARVO), and the American Society of Retinal Specialists. For the last five years he has served as the Macula Society's representative on the Academy's Council, with an emphasis on governmental affairs. Dr. Elman and his wife Linda are actively involved in many community and philanthropic organizations. The Elmans maintain homes in Baltimore, Maryland and in the Jewish Quarter of Jerusalem's Old City. Together, they are the devoted parents of four children and doting grandparents to ten grandchildren.
K. BAILEY FREUND, USA
K. Bailey Freund, MD specializes in all retinal disorders including macular degeneration, diabetic retinopathy, and retinal vascular diseases. He is an expert in retinal imaging and diagnostically challenging and rare conditions. For those reasons he routinely evaluates patients and images from around the world. Dr. Freund has initiated and conducted many clinical trials for treatments for retinal diseases. He is a Clinical Professor of Ophthalmology at New York University School of Medicine. He is a senior partner at Vitreous Retina Macula Consultants of New York, a single-specialty group with ten retinal physicians as well as a multitude of international fellows. He is an attending surgeon at Manhattan Eye, Ear and Throat Hospital and New York Presbyterian Hospital. Dr. Freund is a member of the Retina Society, Macula Society, and the American Society of Retina Specialists. He is on the Editorial Board of the journal Retina and is an Associate Editor for Retinal Cases & Brief Reports. He has authored over 300 peer-reviewed scientific manuscripts and has written numerous books and book chapters, most notably the second edition of The Retina Atlas. He has received numerous awards including the prestigious Young Investigator Award from the Macula Society and the Senior Achievement Award from the American Academy of Ophthalmology. He is a graduate of Williams College and the New York University School of Medicine and completed his residency training in general ophthalmology and fellowship in medical and surgical retina at the Manhattan Eye, Ear, and Throat Hospital. Dr. Freund is also a prominent collector of vintage magic apparatus and a proud husband and father of two.
ALAIN GAUDRIC, FRANCE
Alain Gaudric is an Emeritus Professor of Ophthalmology at University of Paris 7-Denis Diderot, and Lariboisière Hospital, where he was Chair of the Ophthalmology Dept. from 1993 to 2010. Dr Gaudric has received the prize of the Retinal Research Foundation 2006 for his Jules Gonin lecture, the Paul Henkind Award and Lecture of the Macula Society and the EURETINA lecture in 2015. Dr Gaudric's clinical and research interests focus on retinal diseases. He is known for his works on choroidal ischemia, macular hole pathogenesis and surgery, the posterior pole of high myopia, and on OCT interpretation in macular diseases. He has published more than 250 articles in peer-reviewed international journals, as well as 15 book chapters and edited three books. He serves as Associate Editor of the American Journal of Ophthalmology and Editorial Board Member of Ocular Surgery Laser and Imaging, and of Ophthalmologica. Dr Gaudric has been an invited speaker at numerous national and international conferences on a wide range of medical and surgical topics.
MARK GILLIES, AUSTRALIA
Professor Mark Gillies is a clinician scientist who is Director of Research, Save Sight Institute, and of the Macula Research Group of the University of Sydney. The Macula Research Group's clinical research unit has conducted several major investigator-initiated randomized clinical trials, two of which are regarded as seminal, including the first to demonstrate the efficacy of intraocular steroid injections for any ophthalmic disease. The group has also developed an internet-based software tool to track the outcomes of treatment of macular disease in routine clinical practice (the "Fight Retinal Blindness! Project).
Currently the main interests of the Macula Research Group's laboratory include the relationships between retinal glia, blood vessels and neurons in retinal disease. They have developed a unique transgenic mouse in which gene expression can be manipulated specifically in Muller cells. The group has a particular interest in outer retinal metabolism in macular disease and the contribution of Muller cells to photoreceptor metabolism. Mark was a founder member and for many years the Chair of the Scientific Executive Committee of the MacTel Project. Mark holds fellowships from the Sydney Medical School Foundation and the Australian National Health and Medical Research Council. He has published over 200 papers in the peer-reviewed literature.
AGNES GLACET BERNARD, FRANCE
Dr Agnès Glacet-Bernard is Associated Professor at the College of Medicine of the Hospitals of Paris. She practices ophthalmology in the eye department of Creteil (University Paris Est Creteil, Paris XII University, France) headed by Pr Eric Souied, and previously by Pr Gabriel Coscas and then by Pr Gisèle Soubrane,.
She get her MD degree from the University of Paris VI (Faculty of Medicine of Saint Antoine, Pierre & Marie Curie University) and completed her residency through the "Internat des Hôpitaux de Paris" under the direction of well-known French professors in Ophthalmology as Pr Yves Pouliquen, Pr Henri Saraux, Pr Françoise Rousselie and Pr Gabriel Coscas. She also served a fellowship in vitreoretinal diseases and surgery at the ophthalmologic department of Pr Coscas, Creteil, France.
She was recipient of the Christian Zweng Award in 1997, which permitted her to study a new surgical technique on limited macular translocation with Dr Eugene De Juan at the Wilmer Institute (Baltimore, Maryland, USA). She developed this surgical technique at the department of Creteil in patients with subfoveal neovascularization due to age-related macular degeneration, high myopia or inflammation, leading to undreamed-of results before the era of anti-VEGF therapy.
Dr. Glacet-Bernard interests include both vitreoretinal diseases and surgery, and clinical and experimental retinal vein occlusion. She is in charge of the vascular occlusion section at the UPEC ophthalmologic department. She conducted since 1994 several trials in the field of retinal vein occlusion as study coordinator or principal investigator.
She contributed to more than 140 original scientific papers, most of them in peer-reviewed international journals, and to many book chapters. She coordinated the last annual report of the French Societies of Ophthalmology on "Retinal Vein Occlusions" resulting in a 324-page book.
LEE M. JAMPOL, USA
I am a full-time faculty member at Northwestern University. My career has focused on clinical trials, inflammatory diseases of the retina, cystoid macular edema, pharmacology of the retina and central serous chorioretinopathy. I have also been extensively involved in clinical and research work on diabetic retinopathy and age related macular degeneration. Since 1985, when I became a member of the Data Monitoring Committee of the Macular Photocoagulation Study, I have been extensively involved in data monitoring and planning of clinical trials. I have been on the data monitoring committee of the MPS, SST, SCORE and the DRCR. I have been involved with the DRCR since its conception as an active member of the data monitoring committee, helping to monitor data but also to plan the clinical trials. I am presently the Chair of the Diabetic Retinopathy Clinical Research Network (DRCR.net), a U-10 from the NIH supporting research on diabetic retinopathy.I have also served on the external advisory committee of the Latino Eye Study and the Beaver Dam Study. Clinically, I remain active particularly in the area of white spot syndromes of the retina. Administratively, I have been president of the American Ophthalmological Society, trustee and vice president of ARVO, president of the Chicago Ophthalmological Society. I was Chairman of the Department of Ophthalmology at Northwestern University from 1983-2010.
I have also been involved in data monitoring for pharmaceutical companies, including the treatment of uveitis, age related macular degeneration and diabetic retinopathy. In view of conflict of interest concerns, I am presently only a consultant to Stem Cell Organization (with Quintiles and Baxter International) for their studies of age related macular degeneration.
LAURENT KODJIKIAN, FRANCE
Laurent Kodjikian, MD PhD FEBO, is Professor of Ophthalmology (First Class) and Chair of the University of Lyon, France, and Associate Chair of the Department of Ophthalmology, Croix-Rousse Teaching Hospital, Lyon, France. Since 2005, Professor Kodjikian has been on the Boards of the French Agency for Drug Security (ANSM, ex-AFSSAPS) and the National French Health Agency (HAS). Since 2009, he has also been an Expert on Clinical Research Projects in University Hospitals for the French Health Minister. Since 2013, he is administrator of the national FrenchOphthalmological Society (SFO) and Associate General Secretary since 2016. He is a member of numerous scientific societies (ARVO, AAO, Euretina, Club Jules Gonin, SFO). Professor Kodjikian’s research focus is on medical and surgical retina (especially AMD, DR, RVO) and in infections & inflammations (uveitis). He was the principal coordinator of the national GEFAL study (head-to-head study comparing avastin to lucentis in AMD with a budget of 5 millions US dollars). He has been involved in more than 40 clinical trials, examining especially novel therapies for AMD and diabetic retinopathy. He has contributed to more than 200 publications in the ophthalmic literature. Professor Kodjikian is author or co-author of 8 books. He is reviewer for 31 journals (including famous journals like The Lancet). He currently belongs to the Editorial Board of the Journal of Ophthalmology, of the International Journal of Ophthalmology and Clinical Research and of the Journal Français d’Ophtalmologie.
ADRIAN KOH, SINGAPORE
Dr Koh is Founding Partner and Senior Consultant at the Eye & Retina Surgeons, Camden Medical Centre; and Director, Retinal Centre International. He is Visiting Consultant to the Vitreoretinal Service, Singapore National Eye Centre (SNEC), Singapore Eye Research Institute (SERI), National University Hospital Services (NUHS) and Tan Tock Seng Hospital; He is past President of the Singapore Society of Ophthalmology, and member of the Executive Council of the College of Ophthalmologists, Singapore. He also sits on the Council of the Asia Pacific Academy of Ophthalmology (APAO) and Asia Pacific Vitreoretina Society (APVRS). He is the founding Chairman and Honorary Adviser to the Retinitis Pigmentosa Society of Singapore. He was recently appointed Executive Director of ESASO (European School of Advanced Studies in Ophthalmology) Asia. He was Congress Secretary General and Vice President of the APAO Congress 2006 in Singapore; and Congress President of the 5th APVRS in 2010. He is an active member of the Macula Society and Club Jules Gonin. He is a board member of the Vision Academy.
Dr Koh completed Fellowships in Medical Retina at Moorfields Eye Hospital & Institute of Ophthalmology, London, UK (1998 – 1999) and at the Jules Stein Eye Institute, UCLA, Los Angeles, and USA (1999 –2000). The recipient of numerous prestigious awards, Dr Koh has authored or edited many publications in the field of ophthalmology.
His areas of expertise include degenerative macular disease such as choroidal neovascularisation, inherited retinal dystrophy, visual electrophysiology, fundus angiography and retinal vascular disease. He is regarded as one of the key opinion leaders on photodynamic therapy and Lucentis therapy in Asia. He was one of the first surgeons to introduce photodynamic therapy (PDT) in the Asia-Pacific. He is principal investigator of the EVEREST trial studying combination therapy for Polypoidal Choroidal Vasculopathy, and Chairman of the PCV Roundtable of Experts. He was one of the lead investigators in the REVEAL trial evaluating ranibizumab and laser photocoagulation for diabetic macular oedema. He sits on several international advisory boards and steering committees for various clinical trials.
ANAT LOEWENSTEIN, ISRAEL
Anat Loewenstein, MD, MHA is a professor and director of the Department of Ophthalmology at the Tel Aviv Medical Center. Dr. Loewenstein earned her medical degree at the Hebrew University in Jerusalem and completed a residency in ophthalmology at the Tel Aviv Medical Center. Following her residency, Dr. Loewenstein moved to Baltimore for a clinical fellowship in viteroretinal disease at the Wilmer Eye Institute at Johns Hopkins Hospital. Since the year 2000, Dr. Loewenstein is chairing the department of Ophthalmology in the Tel Aviv Medical Center.
Academically she became full professor of Ophthalmology in the Sackler Faculty of Medicine at the Tel Aviv University. Since 2006 she is the Vice Dean of the Sackler School of Medicine, and since this year, Vice dean for academic affairs. In 2010 she became incumbent of the Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine.
Upon her career, Dr. Loewenstein is one of the Israeli and International opinion leaders in the field of Vitreoretinal disease and surgery. From the research point of view, she had more than 280 publications in peer reviewed ophthalmology journals, as well as more than 20 chapters in books. She has been a principal investigator in multiple multicenter drug and device studies, as well as a variety of investigator driven trials. Her main focus of research interest is early detection of macular degeneration including the development of unique technology, drug toxicity of the retina, drug delivery and penetration into the retina, and the treatment of retinal vascular disease.
Prof. Loewenstein serves as an editorial board member in the journal Retina, European Journal of Ophthalmology, Ophthalmologica, Graefes for Archives and Research in Ophthalmology, She is associate editor of the International Journal of Retina and Vitreous and serves as the Editor in Chief in the journal Case reports in Ophthalmology.
In addition, Prof. Loewenstein serves on multiple national committees, including being the chairperson of the National Ethics Review Board committee of the State of Israel Ministry of Health, and she is also a member of the board in the Israeli Council of Surgery and Anesthesia. She is the representative in the International Council of Ophthalmology.
She is also a member in all retina societies, and serves on multiple boards, including being the international representative in the American Society of Retina Specialists as well as macula society boards. She has recently become the General Secretary of the board of the Euretina Society and also a chair in the Academia Ophthalmologica Internationalis. She is also a member in multiple medical advisory boards (Alcon, Allergan, Bayer healthcare (where she belongs to their international stirring committee), Forsightlabs, NotalVision, Novartis).
Prof. Loewenstein received multiple international recognitions and awards, the most important of which are The Macula Society Arnall Patz Medal for outstanding contribution in studies of retinal and macular diseases and Macula Society-Rosenthal Award.
NOEMI LOIS, UK
Noemi Lois is a Clinical Professor of Ophthalmology at Queens University, Belfast, and an Honorary Consultant Ophthalmic Vitreoretinal Surgeon at the Belfast Health and Social Care Trust, Northern Ireland, UK. Prof Lois leads a programme of preclinical and clinical research into diabetic retinopathy and its complications (diabetic macular oedema and proliferative diabetic retinopathy). This programme of research extends from pathogenic mechanisms of disease and risk stratification to new therapies, including determining the most cost-effective therapeutic alternatives for this disease. The value of Prof. Lois current active grants (competitive public or charity funding) is over £2.5 million. Prof Lois has published over 100 articles in peer review journals (Scopus h-index 31), 13 book chapters and is editor of 3 textbooks, one on its second edition. Prof Lois is referee for 22 national and international peer-review journals and six grant bodies, has given over 40 lectures as guest speaker at national and international meetings and is editorial board member of three international journals. Prof Lois has participated, as member of the Evidence Review Group, in 10 Single Technology Appraisals for the UK National Institute of Health and Care Excellence (NICE) on new therapies for eye diseases.
BRUNO LUMBROSO, ITALY
PASCALE MASSIN, FRANCE
Pascale MASSIN was trained in University of Paris. She performed her fellowship at Paris Sorbonne University (Lariboisiere Hospital). She is Professor of Ophthalmology and served as chairman of the Ophthalmology department of Lariboisiere until 2013. She is currently practicing as Retina specialist in private practice and in the department of Diabetology of Lariboisière of Creteil. Her main field of interest is medical and surgical retina, most especially patient management of diabetic eye complications,. She authored more than 150 papers, most of them in peer-reviewed international journals.
JORDI MONES, SPAIN
Dr. Jordi Monés is an M.D., Ph.D., Ophthalmologist, Macula and Vitreorretinal Specialist and Researcher. Since 2007, he is Director of the Institut de la Màcula (accredited site of the network of excellence in research, European Vision Institute) and the Director, principal investigator and one of the founder governors of the Barcelona Macula Foundation: Research for Vision since 2011. From 2010 to 2015 he's been the Coordinator of Ophthalmology at the Centro Medico Teknon.
Dr. Monés has been also Comissioner and Member of the Board of Directors of Futbol Club Barcelona and responsible of the Medical Department and Performance from 2003-2005, and 2010-2015. He is currently the head commissioner to promote the FC Barcelona Universitas project.
He earned his Medicine and Surgery degree and his PhD cum laude in Medicine and Surgery at the Universitat de Barcelona. He specialized in Ophthalmology at Centro de Oftalmología Barraquer (Universitat Autònoma de Barcelona). He got his Retina Specialist degree at The Massachussets Eye and Ear Infirmary at Harvard University, and at Hospital San José at the Monterrey Institute of Technology and Higher Education (ITSM).
His research particular fields of interest are macular diseases, choroidal neovascularization, macular degeneration, antiangiogenic therapy, anti PDGF therapy, geographic atrophy, retinal degeneration, retinal transplant, stems cells, gene therapy, macular edema, and vitreoretinal and macular surgery.
As founder and Medical Director of the Barcelona Macula Foundation: Research for Vision (BMF) is dedicated to fight blindness supporting and conducting research in retinal diseases that currently have no treatment. At the BMF, all our resources and endeavours are directed so that macular and retinal diseases do not prevent our patients continuing with their daily activities as normally as possible.
Through collaboration and partnerships with other centres, universities and companies, BMF promote research and innovation projects that enable us to develop technologies and treatments that may be applied in clinical practice and may benefit our patients as soon as possible.
Retina transplant, stem cell translational therapy, optogenetics, prosthesis, new laser applications, new drugs, minimally invasive surgery, imaging and adaptive optics etc. are the lines guiding our present research projects.
For the last twenty years, he's been a researcher in most of the international multicentre clinical trials for the treatment of age-related macular degeneration (AMD). Reference researcher as Principal Investigator in macular degeneration for the last 15 years (TAP, VIP; VER, VISION, RETAANE, GENEVA, AART, EXCITE, BEVASIRANIB, RANEOVASC, etc.).
Currently, he is conducting Clinical and pre-Clinical trials in phases I, II, III and IV and Investigator driven trials (13 trials during 2014). For instance: CHROMA, FOVISTA E10030-02, M-13-056, MACBETH, TREND, FOVISTA OPH 1003, BRIGTHER, CRYSTAL, MPL4DRY, MPL4DRUSEN, ORAL OMEGA 3 DRY/GA, etc.
Dr. Monés is also participating in three major European Union (EU) projects performed by several agencies from different countries. These projects have received funding from the European Union's Horizon 2020 Programme.
- Exploring the combined role of genetic and non-genetic factors for developing AMD: A systems level analysis of disease subgroups, risk factors, and pathways (EYE RISK).
- Integrated use of second harmonic generation (SHG) microscopy to image corneal collagen fibrils and adaptive optics scanning laser ophthalmoscopy (AOSLO) to image the photoreceptors (LITE).
- Innovative PROcurement for Visual Impaired People (PRO4VIP).
He has published widely in scientific journals and specialist books and has given more than 300 talks at international congresses and meetings. He also participates in the organizing committee and scientific committee of several drug workshops and international conferences.
Furthermore, Dr Monés is Member of the Steering Committee at the International Multicenter Clinical Trials Proxima A and Proxima B on Geographic Atrophy (Roche) and Member of the Steering Committee at the International Multicenter Clinical Trials Brighter and Crystal (Novartis). And member of several International Scientific Advisory Boards, such as AMD International Alliance, ERAB Allergan (Irvine, California USA), REONET Novartis (Basel, Switzerland), Ophthotech (Princeton, NY, USA), Notalvision (Tel Aviv, Israel), Eylea Bayer Schering Pharma (Basel, Switzerland).
Finally, he is a member of 12 scientific societies, being the only retina specialist in the Spanish state to become a member of the four most important retina associations of restricted admission: the Macula Society, the Retina Society, the Club Jules Gonin and the American Society of Retina Specialists.
ANTHONY MOORE, UK
Tony Moore graduated from Oxford University Medical School and after completing the residency training program at Moorfields Eye Hospital in London. He then undertook a two-year fellowship in Paediatric Ophthalmology at the Hospital for Children Greta Ormond in London and the Hospital for Sick Children in Toronto. After his return to the U.K. he was appointed Lecturer in Clinical Ophthalmology, at the UCL Institute of Ophthalmology working with Professor Alan Bird. In 1986 he moved to Cambridge University Medical School as a consultant ophthalmologist with a special interest in paediatric ophthalmology and inherited eye disease. In 2001 he moved back to London when he was appointed to the Duke Elder Chair of Ophthalmology at the UCL Institute of Ophthalmology and Moorfields Eye Hospital, London. In December 2014 he moved to UCSF Ophthalmology Department where he is a Professor of Ophthalmology. He has published more than 350 peer reviewed papers and 45 book chapters. He was elected a fellow of the UK Academy of Medical Sciences in 2005. His main research interests are in inherited eye disease particularly those affecting the retina
QUAN DONG NGUYEN, USA
Born in Saigon, Vietnam, and immigrated with his parents and three brothers to the United States in 1980, Dr. Quan Dong Nguyen currently is a Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine.
Dr. Nguyen received his baccalaureate from the Phillips Exeter Academy and his bachelor and master of science degrees simultaneously in Molecular Biophysics and Biochemistry from Yale University. Subsequently, he earned his medical degree at the University of Pennsylvania School of Medicine. He completed an internship in Internal Medicine at the Massachusetts General Hospital and a residency in Ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Dr. Nguyen also completed fellowships in Immunology and Uveitis at the Massachusetts Eye and Ear Infirmary, Ocular Immunology at the Wilmer Eye Institute of the Johns Hopkins Medical Institutions, and medical and surgical retina at the Schepens Eye Research Institute and the Massachusetts Eye and Ear Infirmary.
After completing his education in 2001, Dr. Nguyen joined the faculty at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, as Assistant Professor and then Associate Professor of Ophthalmology and Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chairman of the Department of Ophthalmology and the Inaugural Director of the Stanley M. Truhlsen Eye Institute, and Assistant Dean for Translational Research at the University of Nebraska Medical Center.
Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases, as well as co-investigator on numerous other clinical trials involving novel therapeutic agents. Dr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. Dr. Nguyen and his team were among the first clinician scientists in the world to evaluate aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME); the initial results of these studies served as the foundation for subsequent trials leading to the approval of these pharmacologic agents by the FDA and other regulatory authorities for the indicated diseases. Dr. Nguyen has chaired the United States multi-center READ-2, READ-3, and iDEAL studies, evaluating the potential role of VEGF antagonists, through different pathways, for diabetic macular edema.
Dr. Nguyen has lead the SAVE, and the multi-centered SAVE-2, and STOP-UVEITIS studies to evaluate the role of new pharmacologic agents, including specific interleukin inhibition, in uveitis and ocular inflammatory diseases.
Dr. Nguyen has been elected to many prestigious national and international professional organizations, including the American Academy of Ophthalmology, the Macula Society, the Retina Society, the American Society of Retina Specialists, the American Uveitis Society, the International Ocular Inflammation Society, the Association for Research in Vision and Ophthalmology, the Club Jules Gonin, and the American Ophthalmological Society.
Throughout his career thus far, Dr. Nguyen has been prolific to share his scientific work through numerous manuscripts published in the literature. He serves on the Editorial Board of several journals, including the Journal of Ophthalmic Infection and Inflammation and Ophthalmic Surgery, Laser, and Imaging – Retina, among others. Given his scientific achievements and accomplishments, Dr. Nguyen has been chosen as the Inaugural Editor-in-Chief of American Journal
of Ophthalmology Case Reports, which has been launched in the fall of 2015 as the companion journal to the American Journal of Ophthalmology.
Dr. Nguyen has been very active in Vietnamese medical professional organizations since 1992 when he was still a medical student. In 2004, Dr. Nguyen became the first US medical school graduate to lead the Vietnamese American Medical Association (VAMA) as President; Dr. Nguyen was re-elected as President of the VAMA in 2007 and served until 2010. Dr. Nguyen also served as President of the Vietnamese Medical Association of the Free World from 2005 to 2008. Most recently, Dr. Nguyen has been elected as Chairman of the Board of Directors of the VAMA (2016-2019).
Moreover, Dr. Nguyen has also been very involved in helping to enhance and promote activities of the International Ocular Inflammation Society. Most recently, Dr. Nguyen co-chaired the Scientific Program Committee for the 2011 IOIS Congress in Goa and served on the Executive Committee for the 2013 IOIS Congress in Valencia (Spain). Dr. Nguyen also co-chaired the 2015 IOIS Congress in San Francisco, the first time in its history that the IOIS held its meeting in the United States. Dr. Nguyen has been elected to serve as Secretary General for the Executive Committee of the IOIS for the term 2015-2019. At the Byers Eye Institute at Stanford, Dr. Nguyen has an active uveitis and ocular inflammatory diseases as well as clinical and surgical retina practice while he continues his research in pharmacotherapy and ocular imaging. In addition, he teaches and trains students, residents, and clinical and research retina and uveitis fellows at Stanford.
KYOKO OHNO-MATSUI, JAPAN
Kyoko Ohno-Matsui is a Professor and Chairperson of the Department of Ophthalmology and Visual Science at Tokyo Medical and Dental University (TMDU). She is also the Chief of the High Myopia Clinic of TMDU. She graduated from Yokohama City University Medical School and received her Ph.D. at Tokyo Medical and Dental University. She did postdoctoral fellowship at Wilmer Eye Institute at Johns Hopkins University.
Her research mainly focuses myopia, especially pathologic myopia. The High Myopia Clinic at TMDU was established in 1974, and now registered patients have exceeded 4,000 from all over Japan and from abroad. Based on the long-term progression study, she established international photographic classification of myopic maculopathy. She is especially interested in how eye is deformed in pathologic myopia, and then how eye deformity damages retina and optic nerve. As a method to visualize the shape of the entire globe, she established a new technique called '3D MRI of the eye'. Based on 3D MRI and wide-field fundus imaging, she proposed a novel classification of posterior staphyloma. Using various imaging modalities (especially swept-source OCT), she has been detecting structural abnormalities which occur in various tissues in eyes with pathologic myopia. Currently she is actively working on ultra-wide field OCT imaging to visualize the entire extent of staphyloma in many patients in vivo. Her lab also investigates basic mechanism of myopization and ocular angiogenesis.
Dr. Ohno-Matsui has been the recipient of Young Investigator Award in Japanese Ophthalmological Society and the Excellence in Research Award at TMDU. She has authored or co-authored over 170 manuscripts which were published in prestigious journals like Lancet. She is the active member of Macular Society, Retina Society, and Club Jules Gonin.
DANIEL PAULEIKHOFF, GERMANY
Department of Ophthalmology, St. Franziskus Hospital, Münster, Germany
Daniel Pauleikhoff is Chairman at the department of Ophthalmology, St. Franziskus Hospital, Münster in Germany, Professor of Ophthalmology at the Faculty of Medicine, Essen, Germany and Honorary Professor at Moorfields Eye Hospital/UCL London, GB. He passed his residency in Ophthalmology at the University of Essen, Germany, and a two year fellowship at Moorfields Eye Hospital/Institute of Ophthalmology in London with Professor Alan C. Bird. Daniel Pauleikhoff main research activities focus on pathogenesis, phenotyping and therapy of age-related macular degeneration.
He is principal investigator for various interventional clinical trials in AMD, diabetic retinopathy and retinal vein occlusions and has received many scientific grants for basic science and clinical investigations. He is serving of the editorial boards of several scientific ophthalmological journals and elected Board member of the German Ophthalmological Society. He is President of the German Retina Society since 2012, serving on the board of this society as a vice-president for the previous 4 years. Dr. Pauleikhoff has authored over 170 publications in peer-reviewed journals, and he is editor/coeditor on several books on macular diseases and received several honorary lectures.
JOSE PULIDO, USA
My interest has always been translational work. To see a problem and not do something about it is anathema to me. This has led me to do intravitreal toxicity and ½ life studies of multiple agents including ganciclovir, rituximab and Avastin. I have worked for multiple years at the interface of uveitis and ocular oncology so that I have tried to meld these two diseases by trying to break tolerance to melanomas and thus cause an immune response. This is coming to fruition since we have submitted an IND to the FDA. Most recently, the development of retinal pigment epithelial cells from induced pluripotent stem cells has become of keen interest to me as a model for testing toxicity before doing and thus guiding and decreasing the need for animal studies.
GIUSEPPE QUERQUES, FRANCE
Giuseppe Querques, MD, PhD, is Associate Professor at University Vita-Salute, IRCCS Ospedale San Raffaele, Milan, Italy. Previous Academic appointments as Associate Professor included University Paris Est Créteil, Centre Hospitalier Intercommunal de Créteil, Créteil, France, where he is currently practicing as Senior Consultant.His main topics are Medical Retina (age-related macular degeneration, retinal vascular diseases, inherited macular and retinal dystrophies) and ophthalmic surgery (retina and cataract). Doctor Querques has contributed to more than 270 peer-reviewed articles published mainly in the areas of Medical Retina (age-related macular degeneration, retinal vascular diseases, hereditary retinal diseases, ophthalmic genetics). His current main area of both clinical and laboratory research is focusing on the diagnosis (imaging) and treatment of age-related macular degeneration, retinal vascular diseases, and hereditary retinal diseases. Prof Giuseppe Querques is Editor in Chief of Ophthalmology @ Point of Care (www.pointofcarejournals.com/poc/oapoc).
SAM RAZAVI, FRANCE
Sam RAZAVI is a Tours (France) based medical retinal specialist, trained at Paris followed by a medical retinal fellowship with Professors Gabriel Coscas and Gisele Soubrane in Créteil eye Clinic.
He maintains involvement in clinical research: he is involved as principal investigator in several international clinical trials of new treatments for age related macular degeneration.
ELIAS REICHEL, USA
Elias Reichel, MD, is Professor and Vice Chair for Research and Education at Tufts University School of Medicine in Boston, Massachusetts. Dr. Reichel is also a founder of Hemera Biosciences and of the Boston Image Reading Center. His research is focused on age-related macular degeneration, diabetic retinopathy, hereditary retinal degenerations, and retinal vascular disorders. Dr. Reichel has a research interest in molecular genetics of retinal diseases, gene therapy, optical coherence tomography, and the role of corticosteroids in treating retinal diseases. He has authored over 140 papers and has served as Principal Investigator for over a dozen industry sponsored clinical trials. Dr. Reichel has developed transpupillary thermotherapy, a novel laser treatment for choroidal neovascularization. He has also developed and brought to market several other ophthalmic innovations including a topical anesthetic agent and vitreoretinal surgica instrumentation.
PHILIP J. ROSENFELD, USA
Dr. Philip Rosenfeld is Professor of Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine. His primary clinical and research interests involve macular diseases with a particular focus on age-related macular degeneration (AMD). He has been the principal investigator and study chairman for numerous AMD clinical trials. Dr. Rosenfeld was lead investigator in the Phase I/II/III Lucentis™ (Genentech) trials, and he pioneered the use of Avastin in neovascular AMD, first by performing a study of systemic, intravenous Avastin and then by using Avastin as an intravitreal injection. Dr. Rosenfeld performed the PrONTO Study, which successfully explored the use of OCT-guided, as-needed treatment as an alternative to monthly dosing with Lucentis. Moreover, he has been involved in the development of both spectral domain and swept source OCT angiography, as well as novel OCT algorithms for studying AMD. As a result, several new OCT clinical trial anatomic endpoints were developed and are being used in ongoing investigations to explore new therapies for dry AMD. In 2009, Dr. Rosenfeld designed and initiated a novel Phase II study exploring complement inhibition for the treatment of dry AMD. The trial, known as the COMPLETE Study, used the FDA-approved drug known as eculizumab (Soliris, Alexion Pharmaceuticals), which was administered intravenously for the treatment of dry AMD. Dr. Rosenfeld is currently participating in additional studies involving complement inhibitors, a beta-amyloid inhibitor, a visual cycle modulator, and embryonic stem cell therapies for the treatment of dry AMD.
DANIEL B. ROTH, USA
Dr. Daniel B. Roth joined NJ Retina in 2000. Dr. Roth graduated from Yeshiva University in New York City, where he was valedictorian. He received his MD from the Yale University School of Medicine.
Dr. Roth completed his residency in ophthalmology at the Bascom Palmer Eye Institute in Miami. He was accepted into the Alpha Omega Alpha Honor Society and received awards by the Fight for Sight Research Foundation, Howard Hughes Research Institute, and ARVO (Association for Research in Vision and Ophthalmology). Dr. Roth completed his fellowship training in vitreoretinal disease and surgery at the Cleveland Clinic.
Dr. Roth is a Clinical Associate Professor in Ophthalmology at Rutgers Robert Wood Johnson Medical School and is involved in teaching medical students and fellows. Dr. Roth is the principal investigator (PI) for multiple national and international clinical trials and has been elected by his peers for inclusion in Best Doctors of America and has received awards for scientific achievement from the AAO (American Academy of Ophthalmology) and ASRS (American Society of Retinal Specialists). Dr. Roth has published more than 75 papers in peer-reviewed literature, as well as numerous articles, textbook chapters and scientific abstracts. He has researched, published, and lectured at national meetings on numerous topics in ophthalmology, including age-related macular degeneration, macular hole repair, endophthalmitis, choroidal melanoma, submacular surgery, retinal vascular occlusion, retinopathy of prematurity, and ocular trauma.
Dr. Roth has developed innovative approaches to treating retinal diseases and serves as a manuscript referee for Ophthalmology, the Journal of the American Academy of Ophthalmology, Retina, The Journal of Retinal and Vitreous Diseases, American Journal of Ophthalmology, Journal of Ocular Pharmacology and Therapeutics and the British Journal of Ophthalmology.
SRINIVAS SADDA, USA
Srinivas R. Sadda, MD, is the President and Chief Scientific Officer of the Doheny Eye Institute, the Stephen J. Ryan – Arnold and Mabel Beckman Endowed Chair, and Professor of Ophthalmology at the University of California – Los Angeles (UCLA) Geffen School of Medicine. He received his MD from Johns Hopkins University, where he also completed ophthalmology residency and neuro-ophthalmology and medical retina fellowships (Wilmer Eye Institute).
Dr Sadda's major research interests include automated retinal image analysis, retinal substructure assessment, and advanced retinal imaging technologies. He has more than 330 peer-reviewed publications and 13 book chapters, and has given over 350 presentations worldwide. Dr. Sadda also serves as an editorial board member of Ophthalmic Surgery, Lasers & Imaging, Retina, Graefe's, Ophthalmology Retina, and Ophthalmology. He is also an editor of the 5th edition of the Ryan's Retina textbook. Among Dr. Sadda's awards and honors are a Research to Prevent Blindness Physician-Scientist Award, a Senior Honor Award from the American Society of Retina Specialists, an Achievement Award and a Secretariat Award from the American Academy of Ophthalmology, John H. Zumberge Research and Innovation Award, and the Macula Society Young Investigator Award. He has been named to the Best Doctors of America list for several consecutive years.
DAVID SARRAF, USA
Dr. David Sarraf is Clinical Professor of Ophthalmology at the Stein Eye Institute at UCLA and member of the Retinal Disorders and Ophthalmic Genetics Division. He has published over 150 research papers, case reports, reviews and book chapters and is co-author for the second edition of the Retina Atlas.
Dr. Sarraf's focus of research interest is the dry and wet forms of age-related macular degeneration (AMD) and specifically the evaluation of pigment epithelial detachment and retinal pigment epithelial tears. He was nominated to the American Ophthalmological Society because of his research work on the subject of PED and AMD.
Dr. Sarraf is a world leader in the field of advanced retinal imaging and has published extensively in the area of spectral domain OCT analysis of AMD and other novel and established macular disorders. He was one of the first researchers to describe ischemia of the deep retinal capillary plexus using advanced SD OCT imaging and is an international expert on the clinical application of OCT angiography.
Dr. Sarraf is an associate editor for the journal Retinal Cases and Brief Reports and is an editorial board member of the journals Retina and OSLI Retina. He has served on the BCSC section of the AAO that has completed the most recent edition of the Retina volume and has been awarded Achievement and Secretariat awards by the AAO.
Dr. Sarraf is also co-director of the Pacific Retina Club and the International Retinal Imaging Symposium and is a member of the ASRS, Retina Society and Gass Club and has served as an executive board member in the Macula Society. He also serves as an advisory board member of the DRCR Network and Optovue Inc.
JOHANNA SEDDON, USA
Dr. Seddon is an internationally known practicing ophthalmologist, retina specialist and genetic epidemiologist at Tufts Medical Center, New England Eye Center in Boston, MA, USA, where she is the Founding Director of the Ophthalmic Epidemiology and Genetics Service, and Professor of Ophthalmology at the Tufts University School of Medicine. Dr. Seddon has an MD degree from the University of Pittsburgh School of Medicine and a Master of Science degree in Epidemiology from the Harvard School of Public Health. She completed Harvard fellowships in Ophthalmic Pathology and Vitreo-Retinal Diseases. She began Genetic and Epidemiologic Studies of Macular Degeneration and Other Eye Diseases in the 1980's which include macular degeneration, Stargardt Disease, Best Disease, other macular dystrophies and high myopia. She is recognized for her groundbreaking research of nutritional factors and eye diseases, specifically initial findings of the beneficial effects of dietary lutein, zeaxanthin, and omega-3 fatty acids on macular degeneration, and she co-authored a science-based cookbook "Eat Right for Your Sight". As Principal Investigator of research grants, she and her team of collaborators made novel discoveries of numerous common and rare genetic variants associated with macular degeneration. She also found biologic and genetic-environmental factors associated with early and late onset forms of macular degenerations. Dr. Seddon and her lab initiated prediction models that combine several genes and lifestyle factors related to progression of macular degeneration, and validated the model. These models are being used in clinical research studies and may eventually be useful for personalized medicine. www.seddonamdriskscore.com. Dr. Seddon has received several awards for her contributions to research and ophthalmology, including the Research Award of Merit from Service d'Ophtalmologie Hôpital Intercommunal de Créteil, "Prix Soubrane de la Recherche en Ophtalmologie", Paris, France, Distinguished Alumni Fellow Award from the University of Pittsburgh, the Philip S. Hench, MD, Alumnus Award from the University of Pittsburgh School of Medicine, the Women in Ophthalmology Honor and Mentor Awards, the Ingrid Kreissig Award from the European Retina, Macular and Vitreous Society, and most recently the Mildred Weisenfeld Award at ARVO in May, and the Lucien Howe Medal Award in June, 2017.
OUDY SEMOUN, FRANCE
Oudy Semoun received his medical degree from Paris 7 University (France) in 2004. He completed his residency in ophthalmology in 2009. He has completed multiple fellowships in ophthalmology from the University of Paris 6 (France) at the Quinze-Vingts National Ophthalmologic Hospital, and Paris Est Créteil University (France). Since residency, he obtained a Master's degree in pharmacology from University Paris 5 (France) in 2010. His main area of interest is focusing on imaging and treatment of retinal diseases, and vitreoretinal and cataract surgery. He is currently working as physician at the Créteil University Eye Clinic (France).
MICHAEL SINGER, USA
Michael Singer is a board-certified Retina, Diabetic, and Macular Degeneration specialist at Medical Center Ophthalmology Associates in San Antonio, TX. Dr. Singer obtained his Bachelor of Arts and his Doctorate of Medicine from Boston University in Massachusetts. Dr. Singer is dedicated to the advancement of ophthalmology, and thus has spent much of his career researching new treatments for conditions, such as diabetes and macular degeneration and has been involved with numerous clinical trails. Dr. Singer has been recognized for his contributions in ophthalmology and has been honored with awards, such as The American Society of Retina Specialist Honor and Senior Award, The Edgar Thomas Award, and the American Academy of Ophthalmology Achievement Honor Award. Dr. Singer has published his findings in numerous medical journals and has traveled internationally to present his work to the ophthalmology community. He is currently Associate Professor at UT Health Science Center in San Antonio, TX., He has been involved in resident education and is a reviewer for multiple ophthalmic medical journals. Dr. Singer is also a family man and resides in San Antonio with his wife and two children.
SOBHA SIVAPRASAD, UK
Sobha Sivaprasad is the Professor of Retinal Clinical Studies in the Institute of Ophthalmology, University College London. She is a Consultant Ophthalmologist at Moorfields Eye Hospital specialising in Medical Retina. Her higher research degree was on age related macular degeneration. She obtained her Medical Retina Fellowship from Moorfields Eye Hospital.
Dr Sivaprasad has active clinical and laboratory research interests in AMD, diabetic retinopathy and retinal vascular disorders. Her research focuses on biomarkers and modeling of retinal morphology in retinal diseases. She oversees several multicentre clinical trials in these areas and has over 150 peer-reviewed publications to her credit. She is an Editor of two eye journals and peer reviewer of several ophthalmic journals.
THEODORE SMITH, USA
R Theodore (Ted) Smith MD PhD is Director of Retinal Imaging and Professor of Ophthalmology at NYU School of Medicine. He received a BA in Mathematics from Rice University summa cum laude, and a PhD in Mathematics from Warwick University, England, where he was a Marshall Scholar. He held mathematics teaching positions at MIT and Columbia before turning to medicine. His MD degree is from the Albert Einstein College of Medicine. He completed a residency in Ophthalmology at the Harkness Eye Institute of Columbia University, and a retina fellowship at the University of Illinois, Chicago. He has more than thirty years of experience in ophthalmology clinical practice, retinal imaging, and research in retinal degenerations, with over 200 publications and meeting presentations on retinal diseases .As Professor of Ophthalmology and Biomedical Engineering at Columbia he founded the Retinal Imaging Laboratory, now at NYU, funded by two NIH R01 grants and by an Individual Investigator Award from the Foundation Fighting Blindness. His conducts clinical studies, especially on age-related macular degeneration, with an emphasis on advanced retinal imaging and diagnostics for accurate patient evaluation at the cellular and molecular level.
A major focus of his research has been the high-risk AMD phenotype of reticular macular disease (RMD), characterized by subretinal drusenoid deposits and choroidal thinning. RMD is highly associated with late AMD, as well as decreased longevity. He has published recently on the association between RMD and systemic disease, including coronary artery disease and kidney diseas
His research group also developed a specially modified confocal scanning laser ophthalmoscope to measure quantitative autofluorescence, or qAF. These measurements have advanced the field by quantifying the fluorescence associated with lipofuscin, an important biomarker in retinal degenerative diseases, Publications on normal retinas, Best disease and Stargardt disease, are currently being followed by work in AMD.
HIs group in collaboration with Christine Curcio developed a hyperspectral autofluorescence imaging system for ex vivo analysis of the retinal pigment epithelium fluorophores. They have found spectral signatures of at least 3 families of abundant RPE fluorophores that are present in both normal eyes and In AMD eyes, and a unique spectrum that is sensitive and specific for drusen and sub-RPE deposits. Identifying these compounds through collaboration with experts in organic chemistry and imaging mass spectrometry may elucidate disease processes, and ultimately lead to a clinical device.
ERIC SOUIED, FRANCE
Eric SOUIED earned his MD and PhD degrees in 1990-2006, at the University Paris Est (UPE). He completed his ophthalmology residency with Pr Gabriel Coscas (1991-2006) and subsequently his fellowship with Pr Gisele Soubrane (2006-2010), two international leaders in the field of medical macula. He also accomplished a post-doctoral fellowship on gene therapy at the Jules Stein Eye Institute, UCLA, with Pr Deborah Farber and Pr Steve Schwartz.
Professor Eric H Souied has contributed to more than 240 peer-reviewed publications in the areas of age-related macular degeneration (AMD), hereditary retinal diseases, ophthalmic genetics and multimodal imaging.
He began in the field on genetics in 1993 with Pr Arnold Munich, working on genetics of retinitis pigmentosa and Stargardt disease. In 1995, he had a precursor vision on the pathogenesis of AMD and decided to investigate a novel hypothesis: the role of genetics in AMD. In 1998 he published in the AJO the first paper about a genetic polymorphism, on the ApoE gene, and AMD. Then, Eric leaded many other genetic studies on AMD, including analysis of CFH and ARMDS2 polymorphisms, phenotype genotype correlations, contribution to international consortium and personalized medicine. Because ApoE gene plays an important role in the lipid pathways, Eric investigated in parallel the role of environmental factors such as fatty acids in the occurrence of AMD (2002-2012). In 2013, he published the first interventional study about oral DHA in the prevention of exudative AMD, the NAT2 study.
Besides these studies on genetic and environmental factors on AMD, Eric also considered phenotyping AMD. He leads a dynamic group focused on multimodal imaging of the macula. They published many papers describing angiographic, SD-OCT, enface-OCT, adaptive optics and OCT angiography features in many macular conditions such as juvenile drusen, reticular pseudodrusen, chrorioretinal anastomosis, adult-onset foveomacular vitelliform dystrophy, geographic atrophy, …
In addition, Eric explored emerging therapies and protocols for AMD, DME, RVO, including anti VEGF treatments. He has led or participated to several studies engaged in exploring new therapeutics.
In 2006, the Paris Est University attributed him a full time professor position and, in 1999, his hospital designed him as head of department of ophthalmology at both "Hopital Intercommunal de Creteil" and "Henri Mondor" hospital, in France. He managed to surround the best elements in France and promote their career. He is the founder president of the French "Association DMLA" and the founder president of the French society "Federation France Macula".
RICHARD F. SPAIDE, USA
Richard F. Spaide, MD is a specialist in retinal diseases and has published more than 300 articles in peer-reviewed journals, nearly 50 book chapters, and edited several books. He is a graduate of Muhlenberg College and Jefferson Medical College in Philadelphia. He completed his Ophthalmology Residency at St. Vincent's Hospital and Medical Center in New York and his Retina Fellowship at the Manhattan Eye, Ear, and Throat Hospital. He is in private practice at the Vitreous, Retina, Macula Consultants of New York. His major research interests include macular diseases, retinal surgery, and ocular imaging. Past highlights in his published papers include indocyanine angiography, fundus autofluorescence, characterization of central serous chorioretinopathy, application of mechanical engineering principles to macular hole formation, development of concepts concerning oxidative damage and characterization of lipid peroxides in Bruch's membrane, combination therapy for age-related macular degeneration, and development of new methodologies to image the retina and choroid. His current research interests include multimodal imaging, optical coherence tomography angiography, and new computer-based rendering techniques to visualize retinal anatomy. Dr. Spaide has been cited in multiple Who's Who and Best Doctors lists and has received many awards including the Richard and Linda Rosenthal Foundation Award in the Visual Sciences, Prix Soubrane de la Recherche en Ophthalmologie, Award of Merit from the Retina Society, Henkind Award, Coscas Award, Nataraja Pillai Award from the Vitreoretinal Society of India, W. Richard Green MD Award, George Theodossiadis Award from the Greek Retinal Society, Founders Award from the American Society of Retinal Surgeons, Life Achievement Honor Award from the American Academy of Ophthalmology, Simon Gratz Award from Thomas Jefferson University, and the Roger Johnson Award in Macular Degeneration Research. He is on the Editorial Board of several journals, an Associate Editor of the journal Retina, and a former Executive Editor of the American Journal of Ophthalmology.
MAYER SROUR, FRANCE
Mayer Srour is is currently fellow in the department of Ophthalmology at the "Hopital Intercommunal de Creteil" in France since May 2014, chaired by Professor Eric Souied an international leader in the field of medical macula. His main areas of scientific interest are age-related macular degeneration, retinal vascular disease, imaging, macular dystrophy and ophthalmic surgery (vitreo-retinal surgery, cataract).
Mayer Srour has contributed to 22 articles published in the areas of age-related macular degeneration, hereditary retinal diseases and imaging.His main area of research is focusing on imaging and treatment of age-related macular degeneration.
He is a active member of Federation France Macula (FFM) and Societe d'OCT Angiographie Francophone (SOAF). Srour is co-author of 5 books devoted to age-related macular degeneration and OCT-angiography.
He is in charge of Maculart's scientific program since 2015.
GIOVANNI STAURENGHI, ITALY
Giovanni Staurenghi is currently professor of ophthalmology, chair of the University Eye Clinic and director of the University Eye Clinic Department of Biomedical and Clinical Sciences "Luigi Sacco" at Luigi Sacco Hospital in Milan, Italy and director of Residency Program at the same University. He was awarded his degree at the University of Pavia, Italy, in 1986, and completed his residency at the University of Milan in 1990. He was a research fellow at the Schepens Eye Research Institute in Boston, Massachusetts, USA, from 1991 to 1992 and visiting scientist at the same institute from 1992 to 1993. He became associate professor in 1999 and was promoted to full professor in 2007.
Professor Staurenghi is a scientific advisor of the Digital Angiography Reading Center and visiting professor and consultant for the Belfast Ophthalmic Reading Center at the Central Angiographic Resource Facility. He is also a member of the editorial board of Investigative Ophthalmology and Visual Science, Retina, American Journal of Cases, and acts as a reviewer for many international scientific journals. He is silver fellow of ARVO. Professor Staurenghi's research, publications and lectures have an important bearing on retinal degeneration; in particular, his work is focused on different types of imaging and treatment. He was awrded with the Coscas medal, and give name lectures such as Junius Kuhnt lecture and the Heinrich Müller lecture. He has been a member of ARVO since 1988, the Macula Society since 2004, the Ophthalmic Photographers' Society since 2006, and the AAO since 2007. He was part of the Annual Meeting Program Committee for ARVO from 2008 to 2010.
LAWRENCE A. YANNUZZI, USA
Dr. Lawrence A. Yannuzzi aspired to be a musician at Arts High School for Music and Art. Limited in musical talent, he attended Harvard College to study mathematics. Following a brief experience in computer programming at IBM, he attended Boston University Medical School, where he eventually was given the Award of Distinguished Alumnus in 1989. Later he was honored as a distinguished alumnus of Boston University in 2006. His ophthalmology residency was at the Manhattan Eye, Ear & Throat Hospital. As director of its residency program, he also followed J. Donald Gass as a guiding mentor and inspiration to initiate and head the medical-retinal service, introducing fluorescein angiography to the Greater New York Community. He also received a grant to start a laser photocoagulation service, utilizing the first commercial Coherent argon laser in the Greater New York Area. Along with Dr. Ronald Carr and Dr. Paul Henkind, he organized and led the New York Retinal Club which eventually evolved into the Atlantic Coast Retinal Club when combined with Dr. Jerry Shields in Philadelphia and Dr. Stuart Fine in Baltimore.
Throughout his professional career, his emphasis has been on teaching and research in the area of medical-retinal diseases. A classification for the interpretation of abnormal fundus fluorescence was reported and used by a generation of retinal specialists. This method of reading fluorescein angiograms was the basis of a textbook, Interpretation of Fundus Fluorescein Angiography with co-authors headed by Dr. Howard Schatz. He was also instrumental in the development of ophthalmic lasers which included the Krypton-Red laser and the multi-colored tunable dye laser.
Among his other clinical contributions was the development of digital indocyanine-green (ICG) angiography by incorporating a Kodak camera, heavily weighted in the near-infrared, a distinct filter combination to enhance the fluorescence of the dye in the choroid, and high-resolution digital images. A textbook on the Interpretation of Indocyanine-Green Angiography followed. Standard references on the potential adverse reactions to intravenous fluorescein and indocyanine-green angiography were also reported by him.
Over the years, he described several new diseases of the fundus and newly-recognized manifestations of known diseases, based principally on their clinical and angiographic findings. These included cystoid macular edema and the use for the first time in the field of ophthalmology a topical, commercially available non-steroid anti-inflammatory topical agent (Indomethacin), and an array of findings in central serous chorioretinopathy (CSC) including its relationship to corticosteroids and sympathomimetic amines in his AOS thesis on Type A Behavior as risk factors for the disease. In this peculiar maculopathy, he also separately described in depth the advent and nature of descending atrophic pigment epithelial tracts from chronic detachment of a macula and gravitating, inferior peripheral detachments, the use of indocyanine-green angiography in CSC as a guide for treating hyperpermeable areas in the choroid with photodynamic therapy to resolve neurosensory retinal detachments. One of the new diseases described in the macula was Acute Idiopathic Maculopathy; another was peculiar posterior choroidal inflammatory/occlusive disease that looked like Serpigenous Choroidopathy and Acute Placoid Pigment Epitheliopathy based on manifestations of both of those disorders, which he named described "Ampigenous" but later termed Relentless Chorioretinitis. In another disease he originally called "Macular Serpiginous," he joined other authors to describe this entity as Persistent Placoid Pigment Epitheliopathy. Perhaps the most relevant of his contributions are applications of indocyanine-green angiography, including the identification of variants in choroidal neovascularization, particularly at risk in individuals who are pigmented….specifically Polypoidal Choroidal Vasculopathy or PCV. Another variant of neovascular Age-Related Macular Degeneration (AMD), which involves principally the retinal vascular layers, known as Retinal Angiomatous Proliferation or "RAP," (now called Type III neovascularization) was discovered by him. He also has contributed to our understanding of Macular Telangiectasia Type II, Multifocal Choroiditis with Zonal Atrophy, Multiple Evanescent White Spot Syndrome, (MEWDS), Focal Retinal Phlebitis and Branch Retinal Vein Occlusion, Acute Zonal Occult Outer Retinopathy, and more recently, Idiopathic Acute Polymorphous Vitelliform Chorioretinopathy.
Through his development and leadership, he founded The Macula Foundation, Inc., and the LuEsther T. Mertz Retinal Research Center of the Manhattan Eye, Ear & Throat Hospital which has been instrumental in the support of teaching programs, basic clinical scientific research, teaching, meetings, and numerous innovative, original and lasting publications for nearly 30 years. In the past three years, the foundation has supported 70 – 90 annual publications, predominantly in peer-review journals.
In the course of his career, he has been acknowledged for his accomplishments, receiving virtually all of the major awards in the area of medical-retinal disease from regional, national and international institutions and societies. These include an Honorary Doctorate by the University of Ancona, the Michelson Award for Retinal Vascular Disease, the Henkind, Gass, and Patz Medals by The Macula Society, the Alcon Research Award, the Herman Wacker Award of the Club Jules Gonin, the Retinal Research Award and the Gass Medal from the Retina Society, the Arthur J. Bedelle Award, the Kreissig Award from EuroRetina, the Bietti Medal, the Pisart Award from the Lighthouse International, and a Lifetime Achievement Award by the American Academy of Ophthalmology. He has also personally published more than 500 clinical-scientific papers and edited and/or authored 14 books. One of his most recent books, The Retinal Atlas, was the recipient of the Prose Award as an outstanding medical academic publication. It has been translated into eight languages worldwide, and it has now become a standard for teaching and reference in retinal disease.
His motto as a teacher and clinical scientist, was once characterized by a noted former fellow as, "Always conduct yourself professionally in the best interest of your patients"….and another….. "What is best for residents and fellows is best for the academic program and its affiliated institutions."…and another….. "Family first." With regard to his perspectives on his most important achievements, he by far considers a marriage which is now over fifty years in duration, three wonderful and successful children: a pediatric psychiatrist, a banker, and a resident in ophthalmology, as well as parents of seven wonderful and loving grandchildren. Above all, they are good friends who find time to spend with each other and their parents.
MARCO ATTILIO EUGENIO ZARBIN, USA
Dr. Zarbin graduated from the Johns Hopkins University School of Medicine (Medical Scientist Training Program, αθα). Dr. Zarbin completed resident and fellowship training (vitreoretinal surgery and medical retina) at the Wilmer Ophthalmological Institute and was an Assistant Chief of Service at Wilmer. Dr. Zarbin is Chair of the Institute of Ophthalmology and Visual Science, Rutgers-New Jersey Medical School and Chief of Ophthalmology at University Hospital in Newark, N.J. He is a Professor of Ophthalmology and Neuroscience and is the Alfonse A. Cinotti, MD/Lions Eye Research Chair. Dr. Zarbin is co-Director of the Ocular Cell Transplantation Laboratory. Dr. Zarbin has published 207 peer-reviewed papers and editorials, 99 book chapters, 190 abstracts, one book on age-related macular degeneration, one book on stem cell therapy for degenerative retinal disease, and one book on the management of diabetic retinopathy. Dr. Zarbin is a NEI-NIH-funded investigator. Dr. Zarbin is a Vice Chair of the Scientific Advisory Board of the Foundation Fighting Blindness, Editor-in-Chief of Translational Vision Science and Technology, and an ex officio member of the National Advisory Eye Council. He is also a member of the American Ophthalmological Society, Academia Ophthalmologica Internationalis, the Retina Society, the Macula Society, the Gonin Society, and the ASRS.